1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • January 2017
  • 465 pages
  • GlobalData
Report ID: 2788800

Summary

Table of Contents

Search Inside

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

Summary
Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: Angiogenesis and EGFR inhibitors.

It is estimated that the value of the Colorectal Cancer (CRC) market in the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and China in 2015 was USD 8.15Billion. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. Just under half of these sales, USD 3.72Billion (46%), were generated in the US, with the 5EU representing the next largest region by sales, estimated at USD 2.71Billion (33%). Japan and China contributed the smallest proportion of sales to the global CRC market, with 2015 sales of USD 980Million (12%) and USD 735Million (9%), respectively.

By 2025, the end of the forecast period, projects CRC sales to rise to $10.97billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 3.0%. In particular, GlobalData expects the Chinese CRC market to experience the highest growth, increasing to $1.25billion (11% total market share) by 2025, at a CAGR of 5.5%.

Major drivers of the growth of the CRC market over the forecast period include -
- Aging populations and rising incident cases of CRC across most markets (except the US) covered in this report is responsible for the forecasted market size growth. Overall, across the 8MM, the incidence of CRC is expected to increase by an Annual Growth Rate (AGR) of 2.2% from 2015-2025.
- The launch and uptake of premium-priced therapies will drive the growth in the CRC market.
- It is expected that the branded drugs to facilitate the gradual increase in the number of patients receiving branded therapy across different lines of metastatic therapy, thus increasing the patient pool of these segments and the overall CRC market size.

The report “PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025” provides an overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

It also provides the following -
- Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
- Provides strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned this report: AB Science, Amgen, Array BioPharma, AstraZeneca, Bayer, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, BTG International, Daiichi-Sankyo, Cleveland Biolabs, Eli Lilly, GlaxoSmithKline, Gradalis, Hutchinson Medi Pharma, Immunomedics, Immunovative Therapies, Jiangsu Hengrui, Merck KGaA, Merck & Co., Merrimack, Mologen, Novartis, PsiOxus therapeutics, Roche/Genentech, Sanofi, Sorrento, Sirtex, Sumitomo Dainippon Pharma, Suzhou Zelgen, Symphogen, Taiho Pharmaceuticals, Takeda, Tracon Pharmaceuticals.

Scope
- Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global CRC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CRC therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Epiomic Epidemiology Series: BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027

  • $ 6859
  • Industry report
  • June 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major Markets It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.